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Treatment is medical risk management. In treatment deci-
sions, the relative risks of interventions have to be weighed
against each other, with long-term irreversible untoward
events being most important to avoid. Resistance develop-
ment is such a deleterious long-term effect, especially with
lower adherence, as it reduces the numbers of options for
successful long-term viral suppression. It is less frequent
with PIs, even with lower levels of adherence. Therefore,
PIs are often used to in order to prevent resistance devel-
opment in settings in which it may otherwise arise. They
represent an attractive option for avoiding exposure to
other drug classes with their associated toxicities, espe-
cially NRTIs, and thus are the backbone of most currently
investigated alternative regimens. Lipid elevations are
common side effects of protease inhibitor therapy (PIs).
Their relevance, however, lies in their association with
clinical events. Not all PIs lead to the same extent of lipid
increase, and not all are associated with myocardial infarc-
tion and stroke. Lipid elevations are reversible after
switching to other regimens, and the associated risk is
time-dependent, so that there remains time to manage
cardiovascular risk. Moreover, in the complex array of car-
diovascular risk factors, lipid elevations are just one factor,
with their relative contribution to risk increasing with age,
and the absolute number of events being low at younger
ages. There are numerous promising interventions for
reducing cardiovascular risk substantially (e.g. smoking
cessation, physical activity, statins), so that avoiding lipid
elevations due to PIs should not be the primary concern.
Long-term viral suppression still remains the most impor-
tant consideration for selecting antiretroviral drugs, as
uncontrolled HIV replication remains the major threat to
long-term health of an infected person. Therefore, despite
a lot of other options, the high genetic barrier to resistance
of PIs reserves them a place in first-line therapy for many
patients.
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